Premium
Triosephosphate Isomerase Inhibitors as Potential Drugs against Clostridium perfringens
Author(s) -
BenítezCardoza Claudia G.,
FernándezVelasco Daniel A.,
ViqueSánchez José L.
Publication year - 2020
Publication title -
chemistryselect
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.437
H-Index - 34
ISSN - 2365-6549
DOI - 10.1002/slct.201904632
Subject(s) - clostridium perfringens , gas gangrene , microbiology and biotechnology , triosephosphate isomerase , clostridium , clostridiaceae , antibiotics , anaerobic bacteria , biology , chemistry , bacteria , biochemistry , enzyme , toxin , genetics
Clostridium perfringes is a gram‐positive anaerobic bacillus responsible for various infections in humans and the main cause of diseases such as gas gangrene, bacterial‐associated diarrhea and food poisoning. Resistances to conventional medications have been identified in different strains of C. perfringens . Therefore, the development of new drugs against this bacterium is necessary. Here we use structural information of C. perfringens (CpTIM) and human (HsTIM) triosephosphate isomerase to look for specific CpTIM inhibitors by means of high‐performance virtual detection. We selected nine compounds (C1 ‐ C9) with high probability of CpTIM binding and low potential to bind to HsTIM, these compounds without report of specific use as an antibiotic. We determined that C2 and C4 decrease the activity of CpTIM by approximately 60 %, while HsTIM is not primarily affected (10 %). Therefore, C2 and C4 or their chemical derivatives should be further investigated as potential drugs against Clostridium perfringens .